George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Meeting

9 Mar 2020 11:07

RNS Number : 4455F
4d Pharma PLC
09 March 2020
 

4D pharma plc

 

("4D pharma" or the "Company")

 

Result of General Meeting

 

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutic products, announces that, at the General Meeting held earlier today to enable the proposed issue of a total of 44,000,000 New Ordinary Shares in connection with the Placing and Subscription to raise gross proceeds of £22 million, all Resolutions were duly passed.

 

Further to the Result of Placing announcement made on 18 February 2020, 27,176,920 Subscription Shares and 16,823,080 Placing Shares will be issued. The total number of New Ordinary Shares to be issued pursuant to the Subscription and Placing remains unchanged.

Application has been made to the London Stock Exchange for the 44,000,000 New Ordinary Shares to be admitted to trading on AIM and it is expected that Admission will occur and dealings commence at 8.00 a.m. tomorrow, 10 March 2020.

Total Voting Rights

Following Admission, the Company will have 109,493,842 Ordinary Shares in issue. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. There Company holds no Ordinary Shares in treasury.

Block Admission

A block admission has been made in respect of 22,000,000 shares which may arise from the exercise of Warrants issued in connection with the Fundraising ("Warrant Shares") under the scheme name '4D March 2020 Warrants'. Admission of the block listed shares will also take effect on 10 March 2020. For the avoidance of doubt, the Warrants themselves will not be admitted to Trading on AIM. Each Warrant entitles the holder to subscribe for one Ordinary Share at a price of 100 pence at any time up to 10 March 2025.

 

Definitions

 

Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to them in the announcement made by the Company on 18 February 2020 to announce the launch of the Placing.

 

 

For further information please contact:

4D

 

Duncan Peyton, Chief Executive Officer

ir@4dpharmaplc.com

+ 44 (0)113 895 0130

 

 

N+1 Singer - Nominated Adviser, Joint Bookrunner and Joint Broker

+44 (0) 20 7496 3000

Aubrey Powell / Justin McKeegan / Alex Bond (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

 

Bryan Garnier & Co. Limited - Joint Bookrunner and Joint Broker

+44 (0)20 7332 2500

Dominic Wilson / Phil Walker

 

Chardan - US Placing Agent

David Lederman (Equity Capital Markets)

+1 646 465-9011

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ROMJLMBTMTMMBFM
Date   Source Headline
16th Feb 20237:00 amRNSCancellation - 4d Pharma Plc
15th Feb 20231:16 pmRNSCancellation of admission to trading on AIM
2nd Feb 20233:10 pmRNSUpdated Results from Renal Cell Carcinoma Cohort
16th Jan 202310:15 amRNSResult of Meeting
30th Dec 202212:30 pmRNSUpdate on Administration and Suspension of Trading
16th Nov 20227:00 amRNSBlautix Phase II Clinical Trial Results Published
10th Nov 20222:00 pmRNSMRx0518 SITC 2022 poster presentations
5th Oct 20221:00 pmRNSMRx0518 poster presentations at SITC 2022
29th Sep 202210:00 amRNSUpdate on Suspension of Trading on AIM
24th Aug 20227:00 amRNSPublication of preclinical autism research
4th Aug 20223:33 pmRNSPublication of Joint Administrators' Proposals
1st Jul 20225:33 pmRNSTemporary Pause of Recruitment in Clinical Trials
28th Jun 20226:28 pmRNS4D Pharma receives Notice of Delisting from NASDAQ
28th Jun 20223:15 pmRNSResult of AGM
27th Jun 20225:30 pmRNS4D Pharma
24th Jun 20226:22 pmRNSUpdate on Suspension of Trading
24th Jun 202212:30 pmRNSSuspension - 4D Pharma PLC
24th Jun 202212:30 pmRNSTemporary Suspension
14th Jun 20227:00 amRNSPre AGM-Investor Presentation and Q&A
7th Jun 202211:00 amRNSExercise of Options and Total Voting Rights
27th May 20227:00 amRNSASCO 2022 MRx0518 and Bavencio Trial In Progress
25th May 20221:51 pmRNSAnnual Report and Notice of AGM
17th May 20227:00 amRNSATS 2022 - MRx-4DP0004 Phase I/II Part A poster
1st Apr 20227:00 amRNSFinal Results
24th Mar 202210:50 amRNSHolding(s) in Company
23rd Mar 20227:00 amRNSMRx0518 + Keytruda - Primary endpoint met in RCC
21st Mar 202210:46 amRNSHolding(s) in Company
9th Mar 20227:00 amRNSForm F3 Registration Statement filed with SEC
24th Feb 20227:21 amRNSHolding(s) in Company
23rd Feb 20227:00 amRNSParticipation in Chardan Microbiome Summit
22nd Feb 20227:00 amRNSParkinson’s trial receives FDA IND clearance
18th Feb 20227:00 amRNSRestatement of Interim Results to June 30, 2021
27th Jan 20227:00 amRNSAdditional MRx04 Phase 1/2 asthma data and event
25th Jan 20225:17 pmRNSHolding(s) in Company
20th Jan 20227:00 amRNS4D pharma to host virtual KOL event
6th Jan 202210:07 amRNSHolding(s) in Company
5th Jan 20227:00 amRNSParticipation in Upcoming Investor Conference
4th Jan 20227:00 amRNS4D pharma appoints John Doyle as CFO
4th Jan 20227:00 amRNSGrant of Options
13th Dec 20217:00 amRNS4D pharma Phase 1/2 asthma study Part A results
9th Dec 20217:00 amRNS4D pharma presents IBS Phase 2 microbiome analysis
7th Dec 20212:19 pmRNSHolding(s) in Company
19th Nov 20215:58 pmRNSHolding(s) in Company
11th Nov 20217:00 amRNS4D pharma Jefferies Healthcare Conference
12th Oct 20217:00 amRNSJefferies Next Generation IBD Therapeutics Summit
30th Sep 20217:00 amRNSHalf-year Report
16th Sep 20212:08 pmRNSHolding(s) in Company
15th Sep 20217:00 amRNS4D pharma presents two posters at ESMO Congress
9th Sep 20217:00 amRNSParticipation in Upcoming Investor Conferences
19th Aug 20219:44 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.